Natalizumab for multiple sclerosis.
Saved in:
| Title: | Natalizumab for multiple sclerosis. |
|---|---|
| Authors: | Liu C; West China Medical School, West China Hospital, Sichuan University, Chengdu, China.; Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China., Cai Z; Gastric Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China., Zhao L; Department of Cardiology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China., Zhou M; Department of Neurology, West China Hospital, Sichuan University, Chengdu, China., Zhang L; Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.; Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China. |
| Source: | The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2025 Aug 06; Vol. 8. Cochrane AN: CD015123. Date of Electronic Publication: 2025 Aug 06. |
| Publication Type: | Journal Article; Systematic Review; Meta-Analysis |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
